Archive: Company News
Cellbox Solutions Raises EUR 6.5 Million in Series A1 Financing Round
– CK Ventures, Fraunhofer Ventures, NRW.Venture and Fil Bros join forces with renowned private investors
– Planned expansion of US business and launch of tailored cell therapy shipment solutions
Cellbox Solutions GmbH, a healthcare company providing live cell logistics solutions for research, development and shipment of life-sustaining therapies, today announced the closing of a Series A1 financing round totaling EUR 6.5 million. The round was led by CK Ventures, supported by Fraunhofer Ventures and several new investors such as NRW.Venture, Fil Bros, and experienced private investors. Representatives of the new investors will take an active role on the board of the company and will be announced separately.
Evonik and BellaSeno advance commercialization of 3D-printed, bioresorbable implants
— Expanded partnership of two leading innovators
— Resomer® used in commercial 3D-printed implants for both soft and hard tissue applications
— BellaSeno receives market authorization for fully resorbable implants – custom-made with Resomer®
Essen and Leipzig, Germany. Evonik and BellaSeno, a developer of 3D-printed absorbable scaffolds, are working together to commercialize innovative 3D-printed scaffolds for bone regeneration. The bone scaffolds are made with Evonik’s Resomer® polymers and are used for large and complex bone defects. Both companies initially began collaborating in 2019 on scaffolds for chest wall and breast reconstruction.
Pan Cancer T Appoints Prof. Dr. Chiara Bonini to its Scientific Advisory Board
– Leading European T cell therapy researcher adds further scientific expertise
Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announced the appointment of Prof. Dr. Chiara Bonini to its Scientific Advisory Board.
Prof. Dr. Chiara Bonini is Professor of Hematology at the Università Vita-Salute San Raffaele, School of Medicine, and Deputy Director of the Research Division of Immunology, Transplantation and Infectious Diseases at the San Raffaele Scientific Institute (Milan, Italy). Read more…
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
— Claus Andersson, PhD, joins Rewind´s Board of Directors
Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that it has raised additional funding, with Sunstone Life Science Ventures A/S joining as a new investor and with participation of existing investors Boehringer Ingelheim Venture Fund, M. Ventures, PMV, Gemma Frisius Fonds, and CD3/ KU Leuven.
Claus Andersson, PhD, General Partner at Sunstone Life Science Ventures A/S, will join Rewind Therapeutics´ Board of Directors. Financial details of the transaction were not disclosed.